DOCSLIB.ORG

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition Published OnlineFirst February 21, 2013; DOI: 10.1158/2159-8290.CD-12-0418 RESEARCH ARTICLE Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition Alexandre Puissant 1 , 3 , Stacey M. Frumm 1 , 3 , Gabriela Alexe 1 , 3 , 5 , 6 , Christopher F. Bassil 1 , 3 , Jun Qi 2 , Yvan H. Chanthery 8 , Erin A. Nekritz 8 , Rhamy Zeid 2 , William Clay Gustafson 8 , Patricia Greninger 7 , Matthew J. Garnett 10 , Ultan McDermott 10 , Cyril H. Benes 7 , Andrew L. Kung 1 , 3 , William A. Weiss 8 , 9 , James E. Bradner 2 , 4 , and Kimberly Stegmaier 1 , 3 , 6 Downloaded from cancerdiscovery.aacrjournals.org on September 25, 2021. © 2013 American Association for Cancer Research. Published OnlineFirst February 21, 2013; DOI: 10.1158/2159-8290.CD-12-0418 ABSTRACT Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly for hematologic malignancies. To date, however, genomic biomarkers to direct clinical translation have been lacking. We conducted a cell-based screen of genetically defi ned cancer cell lines using a prototypical inhibitor of BET bromodomains. Integration of genetic features with chemosensitivity data revealed a robust correlation between MYCN amplifi cation and sensitivity to bromodomain inhibition. We characterized the mechanistic and translational signifi cance of this fi nding in neuroblastoma, a childhood cancer with frequent amplifi cation of MYCN . Genome-wide expression analysis showed downregulation of the MYCN transcriptional program accompanied by suppression of MYCN transcription. Functionally, bromodomain-mediated inhibition of MYCN impaired growth and induced apoptosis in neuroblastoma. BRD4 knockdown phenocopied these effects, establishing BET bromodomains as transcriptional regulators of MYCN . BET inhibition conferred a signifi cant survival advantage in 3 in vivo neuroblastoma models, providing a compelling rationale for developing BET bro- modomain inhibitors in patients with neuroblastoma. SIGNIFICANCE: Biomarkers of response to small-molecule inhibitors of BET bromodomains, a new com- pound class with promising anticancer activity, have been lacking. Here, we reveal MYCN amplifi cation as a strong genetic predictor of sensitivity to BET bromodomain inhibitors, show a mechanistic rationale for this fi nding, and provide a translational framework for clinical trial development of BET bromodomain inhibitors for pediatric patients with MYCN -amplifi ed neuroblastoma. Cancer Discov; 3(3); 308–23. ©2012 AACR. See related commentary by Schnepp and Maris, p. 255. INTRODUCTION Modulation of the epigenetic regulators known as “read- ers” has recently emerged as a therapeutic strategy in cancer The interplay between master regulatory transcription treatment. These epigenetic “readers” are structurally diverse factors and specifi c chromatin-associated coactivators is an proteins, which recognize and bind to covalent modifi ca- emerging hallmark of cancer. Cancer genomic discovery efforts tions of chromatin ( 2 ). One important modifi cation associ- continue to reveal mutations in epigenetic modifi ers, and labo- ated with open chromatin and transcriptional activation is ratory efforts to validate functional dependencies are ongo- the side-chain acetylation of lysine residues on histone tails ing ( 1 ). Moreover, notable examples of successful commercial (3 ). The dominant mode of recognition of acetylated lysine development of drugs targeting epigenetic modifi ers have residues is by bromodomains present in 47 human proteins come to the fore, including the development of inhibitors of ( 4–6 ). We and others have described the therapeutic potential enzymatic “writers,” such as DNA methyltransferases for mye- of targeting one bromodomain-containing family impor- lodysplastic syndrome, and inhibitors of enzymatic “erasers,” tant in regulating transcription, epigenetic memory, and such as histone deacetylases for cutaneous T-cell lymphoma. cell growth: The bromodomain and extraterminal domain (BET) family is composed of BRD2, BRD3, BRD4, and BRDT. Numerous hematologic malignancies and the highly malig- Authors’ Affi liations: Departments of 1 Pediatric Oncology and 2 Medical nant solid tumor NUT midline carcinoma are responsive to Oncology, Dana-Farber Cancer Institute; 3 Boston Children’s Hospital; BET inhibition in vitro and in mouse models ( 7–12 ). 4 Department of Medicine, Harvard Medical School; 5 Bioinformatics Graduate Although disease-specifi c indications for drugs modifying Program, Boston University, Boston; 6 The Broad Institute of Harvard Univer- sity and Massachusetts Institute of Technology, Cambridge; 7 Massachusetts epigenetic regulators have been uncovered, precise genomic General Hospital Cancer Center, Harvard Medical School, Charlestown, Mas- biomarkers predictive of treatment response remain elusive. sachusetts; 8 Department of Pediatrics, Helen Diller Family Comprehensive To date, the best validated genetic predictor of response to Cancer Center; 9 Departments of Neurology and Neurosurgery, Brain Tumor BET inhibitors is in a rare genetically defi ned subset of poorly Research Center, University of California, San Francisco, San Francisco, differentiated squamous cell carcinomas (NUT midline car- California; and 10 Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom cinoma), in which the presence of recurrent t(15;19) chro- Note: Supplementary data for this article are available at Cancer Discovery mosomal translocation results in the expression of the twin Online (http://cancerdiscovery.aacrjournals.org/). N-terminal bromodomains of BRD4 as an in-frame fusion A. Puissant and S.M. Frumm contributed equally to this work. with the NUT protein ( 13 ). High-throughput pharmacoge- Corresponding Authors: Kimberly Stegmaier and James E. Bradner, Dana- nomic profi ling offers the opportunity to reveal new insights Farber Cancer Institute, Boston, MA 02215. Phone: 617-632-4438; Fax: into selective responses to drugs in defi ned cancer genotypes. 617-632-4850; E-mail: [email protected] ; and James Initial efforts to connect drug response with genotype in the E. Bradner, [email protected] NCI60 cell line panel have since been expanded to screening doi: 10.1158/2159-8290.CD-12-0418 campaigns in large panels of genetically characterized cancer © 2012 American Association for Cancer Research. cell lines ( 14–17 ). These efforts have revealed both expected MARCH 2013CANCER DISCOVERY | 309 Downloaded from cancerdiscovery.aacrjournals.org on September 25, 2021. © 2013 American Association for Cancer Research. Published OnlineFirst February 21, 2013; DOI: 10.1158/2159-8290.CD-12-0418 RESEARCH ARTICLE Puissant et al. and unexpected connections. For example, the anticipated to JQ1 and a panel of structurally distinct BET bromodo- response to anaplastic lymphoma receptor kinase (ALK) main inhibitors, each of which conferred a dose-responsive, inhibitors in tumors with aberrant ALK activation, such as inhibitory effect on cell viability as well as growth over time lymphoma, non–small cell lung cancer, and neuroblastoma, ( Fig. 1D–F and Supplementary Table S2). The only exception was shown in a screen of more than 600 tumor cell lines ( 15 ). in this cell line panel was NGP, which was comparatively More recently, the unexpected connections between response insensitive to all of the BET bromodomain inhibitors tested. to PARP inhibitors and expression of the EWS/FLI fusion Importantly, cell growth was not affected in any cell lines protein in Ewing sarcoma was elucidated in a screen of 130 by the (−)-JQ1 enantiomer, which lacks activity against BET drugs in more than 600 cancer cell lines ( 16 ). In an independ- bromodomains in biochemical and biologic assays, further ent study of 24 anticancer drugs in 479 human cancer cell supporting an on-target mechanism of action. Similarly, we lines, new connections were also observed between small- retested one of the least sensitive cell lines from the primary molecule sensitivities and cell lineage, gene expression, and screen, the MYCN –wild-type neuroblastoma cell line SK-N- genotype ( 17 ). AS and a second MYCN –wild-type cell line SH-SY5Y not in We conducted a high-throughput pharmacogenomic the primary screen. As predicted, SK-N-AS was insensitive screen to identify biomarkers of response to BET bromodo- to the effects of JQ1, and SH-SY5Y was less sensitive than main inhibitors. The prototype ligand JQ1, a novel thieno- the MYCN -amplifi ed cell lines based on Emax (Supplementary triazolo-1,4-diazepine, which displaces BET bromodomains Fig. S2A and S2B and Supplementary Table S2). from chromatin by competitively binding to the acetyl lysine recognition pocket, has been validated in numerous mod- JQ1 Induces Cell-Cycle Arrest and Apoptosis els, nominating it as an excellent chemical probe for high- To further characterize the phenotypic consequences of throughput screening ( 7–10 ). In this study, we therefore JQ1 treatment on responsive MYCN -amplifi ed neuroblas- queried a large compendium of genetically characterized toma cells, we determined its effects on cell-cycle arrest tumor cell lines to identify predictors of sensitivity to JQ1. We and apoptosis. JQ1 treatment induced a G0 –G1 arrest and a identifi ed MYCN amplifi cation as a top predictive marker of decrease in S-phase at 24 hours by fl ow-cytometric evaluation response to JQ1 treatment and characterized the mechanistic of propidium iodide (PI) staining ( Fig. 2A and Supplemen- and translational signifi cance
Load more

Recommended publications
  • PARSANA-DISSERTATION-2020.Pdf
    DECIPHERING TRANSCRIPTIONAL PATTERNS OF GENE REGULATION: A COMPUTATIONAL APPROACH by Princy Parsana A dissertation submitted to The Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland July, 2020 © 2020 Princy Parsana All rights reserved Abstract With rapid advancements in sequencing technology, we now have the ability to sequence the entire human genome, and to quantify expression of tens of thousands of genes from hundreds of individuals. This provides an extraordinary opportunity to learn phenotype relevant genomic patterns that can improve our understanding of molecular and cellular processes underlying a trait. The high dimensional nature of genomic data presents a range of computational and statistical challenges. This dissertation presents a compilation of projects that were driven by the motivation to efficiently capture gene regulatory patterns in the human transcriptome, while addressing statistical and computational challenges that accompany this data. We attempt to address two major difficulties in this domain: a) artifacts and noise in transcriptomic data, andb) limited statistical power. First, we present our work on investigating the effect of artifactual variation in gene expression data and its impact on trans-eQTL discovery. Here we performed an in-depth analysis of diverse pre-recorded covariates and latent confounders to understand their contribution to heterogeneity in gene expression measurements. Next, we discovered 673 trans-eQTLs across 16 human tissues using v6 data from the Genotype Tissue Expression (GTEx) project. Finally, we characterized two trait-associated trans-eQTLs; one in Skeletal Muscle and another in Thyroid. Second, we present a principal component based residualization method to correct gene expression measurements prior to reconstruction of co-expression networks.
    [Show full text]
  • Arabidopsis Adaptor Protein 1G2 Is Required for Female and Male Gametogenesis
    Arabidopsis adaptor protein 1G2 is required for female and male gametogenesis Yongmei Zhou Fujian Agriculture and Forestry University Wenqin Fang Fujian Agriculture and Forestry University Li-Yu Chen Fujian Agriculture and Forestry University Neha Pandey Fujian Agriculture and Forestry University Azam Syed Muhammad Fujian Agriculture and Forestry University Ray Ming ( [email protected] ) University of Illinois at Urbana-Champaign https://orcid.org/0000-0002-9417-5789 Research article Keywords: Arabidopsis, AP1G2, megagametogenesis, microgametogenesis, development. Posted Date: November 12th, 2019 DOI: https://doi.org/10.21203/rs.2.17134/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/22 Abstract Background: The gametophyte s are essential for the productive process in angiosperms. During sexual reproduction in owering plants, haploid spores are formed from meioses of spore mother cells. The spores then undergo mitosis and develop into female and male gametes and give rise to seeds after fertilization. Results: We identied a female sterile mutant from EMS mutagenesis, and a BC1F2 population was generated for map based cloning of the causal gene. Genome re-sequencing of mutant and non-mutant pools revealed a candidate gene, AP1G2 . Analyses of two insertions mutants, ap1g2-1 +/- in exon 7 and ap1g2-3 -/- in 3’ UTR, revealed partial female sterility. Complementation test using native promoter of AP1G2 restored the function in ap1g2-1 +/- and ap1g2-3 -/- . AP1G2 is a paralog of AP1G1 , encoding the large subunit (γ) of adaptor protein-1 (AP-1). ap1g2 mutation led to defective female and male gametophyte development was determined.
    [Show full text]
  • Computational Genome-Wide Identification of Heat Shock Protein Genes in the Bovine Genome [Version 1; Peer Review: 2 Approved, 1 Approved with Reservations]
    F1000Research 2018, 7:1504 Last updated: 08 AUG 2021 RESEARCH ARTICLE Computational genome-wide identification of heat shock protein genes in the bovine genome [version 1; peer review: 2 approved, 1 approved with reservations] Oyeyemi O. Ajayi1,2, Sunday O. Peters3, Marcos De Donato2,4, Sunday O. Sowande5, Fidalis D.N. Mujibi6, Olanrewaju B. Morenikeji2,7, Bolaji N. Thomas 8, Matthew A. Adeleke 9, Ikhide G. Imumorin2,10,11 1Department of Animal Breeding and Genetics, Federal University of Agriculture, Abeokuta, Nigeria 2International Programs, College of Agriculture and Life Sciences, Cornell University, Ithaca, NY, 14853, USA 3Department of Animal Science, Berry College, Mount Berry, GA, 30149, USA 4Departamento Regional de Bioingenierias, Tecnologico de Monterrey, Escuela de Ingenieria y Ciencias, Queretaro, Mexico 5Department of Animal Production and Health, Federal University of Agriculture, Abeokuta, Nigeria 6Usomi Limited, Nairobi, Kenya 7Department of Animal Production and Health, Federal University of Technology, Akure, Nigeria 8Department of Biomedical Sciences, Rochester Institute of Technology, Rochester, NY, 14623, USA 9School of Life Sciences, University of KwaZulu-Natal, Durban, 4000, South Africa 10School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, 30032, USA 11African Institute of Bioscience Research and Training, Ibadan, Nigeria v1 First published: 20 Sep 2018, 7:1504 Open Peer Review https://doi.org/10.12688/f1000research.16058.1 Latest published: 20 Sep 2018, 7:1504 https://doi.org/10.12688/f1000research.16058.1 Reviewer Status Invited Reviewers Abstract Background: Heat shock proteins (HSPs) are molecular chaperones 1 2 3 known to bind and sequester client proteins under stress. Methods: To identify and better understand some of these proteins, version 1 we carried out a computational genome-wide survey of the bovine 20 Sep 2018 report report report genome.
    [Show full text]
  • Gene Targeting Therapies (Roy Alcalay)
    Recent Developments in Gene - Targeted Therapies for Parkinson’s Disease Roy Alcalay, MD, MS Alfred and Minnie Bressler Associate Professor of Neurology Division of Movement Disorders Columbia University Medical Center Disclosures Funding: Dr. Alcalay is funded by the National Institutes of Health, the DOD, the Michael J. Fox Foundation and the Parkinson’s Foundation. Dr. Alcalay receives consultation fees from Genzyme/Sanofi, Restorbio, Janssen, and Roche. Gene Localizations Identified in PD Gene Symbol Protein Transmission Chromosome PARK1 SNCA α-synuclein AD 4q22.1 PARK2 PRKN parkin (ubiquitin ligase) AR 6q26 PARK3 ? ? AD 2p13 PARK4 SNCA triplication α-synuclein AD 4q22.1 PARK5 UCH-L1 ubiquitin C-terminal AD 4p13 hydrolase-L1 PARK6 PINK1 PTEN-induced kinase 1 AR 1p36.12 PARK7 DJ-1 DJ-1 AR 1p36.23 PARK8 LRRK2 leucine rich repeat kinase 2 AD 12q12 PARK9 ATP13A2 lysosomal ATPase AR 1p36.13 PARK10 ? ? (Iceland) AR 1p32 PARK11 GIGYF2 GRB10-interacting GYF protein 2 AD 2q37.1 PARK12 ? ? X-R Xq21-q25 PARK13 HTRA2 serine protease AD 2p13.1 PARK14 PLA2G6 phospholipase A2 (INAD) AR 22q13.1 PARK15 FBXO7 F-box only protein 7 AR 22q12.3 PARK16 ? Discovered by GWAS ? 1q32 PARK17 VPS35 vacuolar protein sorting 35 AD 16q11.2 PARK18 EIF4G1 initiation of protein synth AD 3q27.1 PARK19 DNAJC6 auxilin AR 1p31.3 PARK20 SYNJ1 synaptojanin 1 AR 21q22.11 PARK21 DNAJC13 8/RME-8 AD 3q22.1 PARK22 CHCHD2 AD 7p11.2 PARK23 VPS13C AR 15q22 Gene Localizations Identified in PD Disorder Symbol Protein Transmission Chromosome PD GBA β-glucocerebrosidase AD 1q21 SCA2
    [Show full text]
  • Seq2pathway Vignette
    seq2pathway Vignette Bin Wang, Xinan Holly Yang, Arjun Kinstlick May 19, 2021 Contents 1 Abstract 1 2 Package Installation 2 3 runseq2pathway 2 4 Two main functions 3 4.1 seq2gene . .3 4.1.1 seq2gene flowchart . .3 4.1.2 runseq2gene inputs/parameters . .5 4.1.3 runseq2gene outputs . .8 4.2 gene2pathway . 10 4.2.1 gene2pathway flowchart . 11 4.2.2 gene2pathway test inputs/parameters . 11 4.2.3 gene2pathway test outputs . 12 5 Examples 13 5.1 ChIP-seq data analysis . 13 5.1.1 Map ChIP-seq enriched peaks to genes using runseq2gene .................... 13 5.1.2 Discover enriched GO terms using gene2pathway_test with gene scores . 15 5.1.3 Discover enriched GO terms using Fisher's Exact test without gene scores . 17 5.1.4 Add description for genes . 20 5.2 RNA-seq data analysis . 20 6 R environment session 23 1 Abstract Seq2pathway is a novel computational tool to analyze functional gene-sets (including signaling pathways) using variable next-generation sequencing data[1]. Integral to this tool are the \seq2gene" and \gene2pathway" components in series that infer a quantitative pathway-level profile for each sample. The seq2gene function assigns phenotype-associated significance of genomic regions to gene-level scores, where the significance could be p-values of SNPs or point mutations, protein-binding affinity, or transcriptional expression level. The seq2gene function has the feasibility to assign non-exon regions to a range of neighboring genes besides the nearest one, thus facilitating the study of functional non-coding elements[2]. Then the gene2pathway summarizes gene-level measurements to pathway-level scores, comparing the quantity of significance for gene members within a pathway with those outside a pathway.
    [Show full text]
  • Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers
    Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers. by Kelly Kennaley A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Molecular and Cellular Pathology) in the University of Michigan 2019 Doctoral Committee: Associate Professor Zaneta Nikolovska-Coleska, Co-Chair Adjunct Associate Professor Scott A. Tomlins, Co-Chair Associate Professor Eric R. Fearon Associate Professor Alexey I. Nesvizhskii Kelly R. Kennaley [email protected] ORCID iD: 0000-0003-2439-9020 © Kelly R. Kennaley 2019 Acknowledgements I have immeasurable gratitude for the unwavering support and guidance I received throughout my dissertation. First and foremost, I would like to thank my thesis advisor and mentor Dr. Scott Tomlins for entrusting me with a challenging, interesting, and impactful project. He taught me how to drive a project forward through set-backs, ask the important questions, and always consider the impact of my work. I’m truly appreciative for his commitment to ensuring that I would get the most from my graduate education. I am also grateful to the many members of the Tomlins lab that made it the supportive, collaborative, and educational environment that it was. I would like to give special thanks to those I’ve worked closely with on this project, particularly Dr. Moloy Goswami for his mentorship, Lei Lucy Wang, Dr. Sumin Han, and undergraduate students Bhavneet Singh, Travis Weiss, and Myles Barlow. I am also grateful for the support of my thesis committee, Dr. Eric Fearon, Dr. Alexey Nesvizhskii, and my co-mentor Dr. Zaneta Nikolovska-Coleska, who have offered guidance and critical evaluation since project inception.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • MBNL1 Regulates Essential Alternative RNA Splicing Patterns in MLL-Rearranged Leukemia
    ARTICLE https://doi.org/10.1038/s41467-020-15733-8 OPEN MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia Svetlana S. Itskovich1,9, Arun Gurunathan 2,9, Jason Clark 1, Matthew Burwinkel1, Mark Wunderlich3, Mikaela R. Berger4, Aishwarya Kulkarni5,6, Kashish Chetal6, Meenakshi Venkatasubramanian5,6, ✉ Nathan Salomonis 6,7, Ashish R. Kumar 1,7 & Lynn H. Lee 7,8 Despite growing awareness of the biologic features underlying MLL-rearranged leukemia, 1234567890():,; targeted therapies for this leukemia have remained elusive and clinical outcomes remain dismal. MBNL1, a protein involved in alternative splicing, is consistently overexpressed in MLL-rearranged leukemias. We found that MBNL1 loss significantly impairs propagation of murine and human MLL-rearranged leukemia in vitro and in vivo. Through transcriptomic profiling of our experimental systems, we show that in leukemic cells, MBNL1 regulates alternative splicing (predominantly intron exclusion) of several genes including those essential for MLL-rearranged leukemogenesis, such as DOT1L and SETD1A.Wefinally show that selective leukemic cell death is achievable with a small molecule inhibitor of MBNL1. These findings provide the basis for a new therapeutic target in MLL-rearranged leukemia and act as further validation of a burgeoning paradigm in targeted therapy, namely the disruption of cancer-specific splicing programs through the targeting of selectively essential RNA binding proteins. 1 Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA. 2 Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA. 3 Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA.
    [Show full text]
  • UNIVERSITY of CALIFORNIA Los Angeles
    UNIVERSITY OF CALIFORNIA Los Angeles Integrating molecular phenotypes and gene expression to characterize DNA variants for cardiometabolic traits A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Human Genetics by Alejandra Rodriguez 2018 ABSTRACT OF THE DISSERTATION Integrating molecular phenotypes and gene expression to characterize DNA variants for cardiometabolic traits by Alejandra Rodriguez Doctor of Philosophy in Human Genetics University of California, Los Angeles, 2018 Professor Päivi Elisabeth Pajukanta, Chair In-depth understanding of cardiovascular disease etiology requires characterization of its genetic, environmental, and molecular architecture. Genetic architecture can be defined as the characteristics of genetic variation responsible for broad-sense phenotypic heritability. Massively parallel sequencing has generated thousands of genomic datasets in diverse human tissues. Integration of such datasets using data mining methods has been used to extract biological meaning and has significantly advanced our understanding of the genome-wide nucleotide sequence, its regulatory elements, and overall chromatin architecture. This dissertation presents integration of “omics” data sets to understand the genetic architecture and molecular mechanisms of cardiovascular lipid disorders (further reviewed in Chapter 1). In 2013, Daphna Weissglas-Volkov and coworkers1 published an association between the chromosome 18q11.2 genomic region and hypertriglyceridemia in a genome-wide
    [Show full text]
  • Downloaded from USCS Tables (
    bioRxiv preprint doi: https://doi.org/10.1101/318329; this version posted February 4, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The selection arena in early human blastocysts resolves the pluripotent inner cell mass Manvendra Singh1, Thomas J. Widmann2, Vikas Bansal7, Jose L. Cortes2, Gerald G. Schumann3, Stephanie Wunderlich4, Ulrich Martin4, Marta Garcia-Canadas2, Jose L. Garcia- Perez2,5*, Laurence D. Hurst6*#, Zsuzsanna Izsvák1* 1 Max-Delbrück-Center for Molecular Medicine in the Helmholtz Society, Robert-Rössle- Strasse 10, 13125 Berlin, Germany. 2 GENYO. Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, 18016 Granada, Spain. 3 Paul-Ehrlich-Institute, Division of Medical Biotechnology, Paul-Ehrlich-Strasse 51-59, 63225 Langen, Germany. 4Center for Regenerative Medicine Hannover Medical School (MHH) Carl-Neuberg-Str.1, Building J11, D-30625 Hannover, Germany 5Institute of Genetics and Molecular Medicine (IGMM), University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, United Kingdom 6 The Milner Centre for Evolution, Department of Biology and Biochemistry, University of Bath, Bath, Somerset, UK, BA2 7AY. 7 Institute of Medical Systems Biology, Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf (UKE), 20246, Hamburg, Germany. *Corresponding authors *Zsuzsanna Izsvák Max Delbrück Center for Molecular Medicine Robert Rössle Strasse 10, 13092 Berlin, Germany Telefon: +49 030-9406-3510 Fax: +49 030-9406-2547 email: [email protected] http://www.mdcberlin.de/en/research/research_teams/mobile_dna/index.html and *Laurence D.
    [Show full text]
  • Análise Integrativa De Perfis Transcricionais De Pacientes Com
    UNIVERSIDADE DE SÃO PAULO FACULDADE DE MEDICINA DE RIBEIRÃO PRETO PROGRAMA DE PÓS-GRADUAÇÃO EM GENÉTICA ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Ribeirão Preto – 2012 ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Tese apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo para obtenção do título de Doutor em Ciências. Área de Concentração: Genética Orientador: Prof. Dr. Eduardo Antonio Donadi Co-orientador: Prof. Dr. Geraldo A. S. Passos Ribeirão Preto – 2012 AUTORIZO A REPRODUÇÃO E DIVULGAÇÃO TOTAL OU PARCIAL DESTE TRABALHO, POR QUALQUER MEIO CONVENCIONAL OU ELETRÔNICO, PARA FINS DE ESTUDO E PESQUISA, DESDE QUE CITADA A FONTE. FICHA CATALOGRÁFICA Evangelista, Adriane Feijó Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas. Ribeirão Preto, 2012 192p. Tese de Doutorado apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo. Área de Concentração: Genética. Orientador: Donadi, Eduardo Antonio Co-orientador: Passos, Geraldo A. 1. Expressão gênica – microarrays 2. Análise bioinformática por module maps 3. Diabetes mellitus tipo 1 4. Diabetes mellitus tipo 2 5. Diabetes mellitus gestacional FOLHA DE APROVAÇÃO ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas.
    [Show full text]
  • Core Circadian Clock Transcription Factor BMAL1 Regulates Mammary Epithelial Cell
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.23.432439; this version posted February 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Title: Core circadian clock transcription factor BMAL1 regulates mammary epithelial cell 2 growth, differentiation, and milk component synthesis. 3 Authors: Theresa Casey1ǂ, Aridany Suarez-Trujillo1, Shelby Cummings1, Katelyn Huff1, 4 Jennifer Crodian1, Ketaki Bhide2, Clare Aduwari1, Kelsey Teeple1, Avi Shamay3, Sameer J. 5 Mabjeesh4, Phillip San Miguel5, Jyothi Thimmapuram2, and Karen Plaut1 6 Affiliations: 1. Department of Animal Science, Purdue University, West Lafayette, IN, USA; 2. 7 Bioinformatics Core, Purdue University; 3. Animal Science Institute, Agriculture Research 8 Origination, The Volcani Center, Rishon Letsiyon, Israel. 4. Department of Animal Sciences, 9 The Robert H. Smith Faculty of Agriculture, Food, and Environment, The Hebrew University of 10 Jerusalem, Rehovot, Israel. 5. Genomics Core, Purdue University 11 Grant support: Binational Agricultural Research Development (BARD) Research Project US- 12 4715-14; Photoperiod effects on milk production in goats: Are they mediated by the molecular 13 clock in the mammary gland? 14 ǂAddress for correspondence. 15 Theresa M. Casey 16 BCHM Room 326 17 175 South University St. 18 West Lafayette, IN 47907 19 Email: [email protected] 20 Phone: 802-373-1319 21 22 bioRxiv preprint doi: https://doi.org/10.1101/2021.02.23.432439; this version posted February 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]